🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Adaptive Biotechnologies Corporation ADPT R2KR3KPHARMA

Healthcare · Diagnostics & Research · United States
https://www.adaptivebiotech.com
Company Profile ↓
$24.41
+87.77% 1Y
Mkt Cap$3.90B
P/E-58.12
P/B29.50
52W High$29.84
52W Low$12.30
Book Value$0.90
EPS (TTM)$-0.42

Company Overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 28.0% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $276.98M (+54.8% YoY); net profit $-59.50M.
  • Trailing 12 Months Year-on-year growth — revenue +21.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 28.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:28.00%
1 Year:21.50%

Stock Price Performance

1 Year:+87.77%
6 Months:+76.63%
3 Months:+9.61%
1 Month:-12.48%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 69% of range
$12.30 $29.84
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)41.51 · Neutral
Price Performance
1M-12.48%
3M+9.61%
6M+76.63%
1Y+87.77%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 28.0% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-58.12
Industry PE
25.61
Forward P/E
-135.27
PEG Ratio
-
Book Value
$0.90
Price to Book
29.50
P/S
13.72
EV/EBITDA
-200.13
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
28.00%
Profit 5Y
-
Revenue (YoY)
21.50%
Earnings (YoY)
-

Profitability & Returns

ROCE
-13.51%
ROE
-38.76%
ROA
-4.12%
Profit Margin
-20.73%
Op Margin
-22.04%
Gross Margin
46.94%
EPS (Latest Qtr)
$-0.25
EPS (TTM)
$-0.42

Balance Sheet & Liquidity

Debt/Equity
2.72
Quick Ratio
4.51
Current Ratio
4.79
Debt
$410.50M
Total Assets
$640.68M
Current Assets
$291.81M
Working Capital
$210.27M

Ownership

Promoter Holding
1.29%
Chg in Prom Hold
-0.01%
FII / Inst Holding
99.50%
Chg in FII Hold
0.09%

Financial Snapshot

Enterprise Value
$3.90B
Total Revenue (TTM)
$308.08M
EBITDA
$-21.33M
Free Cash Flow
$18.98M
Operating Cash Flow
$-21.01M
Shares Outstanding
159.60M
Gross Margin
46.94%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ADPT Adaptive Biotechnologies Corporation R2KR3KPHARMA 24.41 -58.12 $3.90B 0.00% -13.51% -38.76% 28.00% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,306.69 43.95 $1.16T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 267.61 31.05 $644.91B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.19 80.56 $503.96B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 424.98 27.29 $381.46B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 147.24 117.79 $363.27B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 156.27 23.61 $297.02B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 172.57 25.80 $267.64B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 676.54 36.45 $250.15B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 11.57M17.19M12.67M22.14M26.06M20.91M20.99M26.30M38.44M38.51M39.47M38.62M43.66M47.83M37.65M48.93M37.92M41.87M43.19M--52.44M58.88M93.97M71.68M70.87M-
Cost of Revenue ---------------------16.98M18.00M18.16M18.22M18.71M-
Gross Profit ---------------------35.46M40.88M75.82M53.46M52.17M-
Operating Expenses ---------------------65.07M65.92M65.53M66.23M71.37M-
Operating Income -13.31M-9.16M-20.05M-16.11M-18.05M-34.62M-36.91M-37.05M-41.28M-49.77M-56.33M-63.07M-52.50M-45.43M-57.19M-47.82M-50.96M-48.76M-47.32M---29.60M-25.04M10.29M-12.77M-19.21M-
EBITDA ----------------------22.19M-18.14M16.92M-6.43M-13.29M-
Interest Expense ---------------------2.90M2.95M2.97M2.95M2.89M-
Pretax Income ----------------------29.83M-25.59M9.54M-13.58M-20.02M-
Tax Provision ---------------------------
Net Income -12.49M-8.29M-18.39M-15.66M-13.95M-31.40M-33.53M-36.72M-40.64M-49.30M-55.90M-62.74M-52.05M-45.28M-57.70M-47.81M-50.30M-47.51M-46.22M---29.85M-25.61M9.55M-13.58M-20.03M-
Diluted EPS ----------0.35-0.40-0.44-0.37-0.32-0.40-0.33-0.35-0.33-0.31----0.170.06-0.09-0.13-0.25
R&D Expense 9.45M9.78M12.48M16.53M20.51M23.93M25.99M30.31M33.77M37.80M36.07M37.84M37.04M35.66M32.60M32.24M28.53M30.25M25.35M24.16M-24.20M24.13M23.67M-23.62M-

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 38.45M55.66M85.07M98.38M154.34M185.31M170.28M178.96M276.98M
Cost of Revenue -----57.91M75.55M72.08M71.36M
Gross Profit -----127.40M94.72M106.88M205.62M
Operating Expenses -----327.58M296.33M262.22M262.74M
Operating Income -44.48M-49.76M-78.39M-152.82M-208.97M-200.19M-201.61M-155.34M-57.12M
EBITDA ------175.21M-189.27M-128.76M-29.85M
Interest Expense -----4.24M13.80M11.58M11.78M
Pretax Income ------200.37M-225.30M-159.59M-59.46M
Tax Provision ---------
Net Income -42.83M-46.45M-68.61M-146.23M-207.28M-200.19M-225.25M-159.49M-59.50M
Diluted EPS ----1.11-1.48-1.40-1.56-1.08-0.39
R&D Expense 32.00M39.16M70.70M116.07M142.34M141.76M122.12M102.95M93.77M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --332.69M912.30M1.12B-856.62M661.13M539.38M512.74M
Current Assets ------562.15M410.19M283.75M300.19M
Cash & Equivalents --55.03M96.58M123.44M-90.03M65.06M47.92M70.50M
Inventory ------14.45M14.45M8.44M9.82M
Receivables ------40.06M37.97M41.73M50.37M
Total Liabilities --29.94M341.26M373.15M-392.52M352.86M336.89M287.74M
Current Liabilities --22.80M78.31M105.20M-109.79M88.02M98.05M89.92M
Long Term Debt ----------
Total Debt ------108.00M98.77M89.39M79.15M
Total Equity -189.73M-224.62M-258.11M571.04M743.27M-464.17M308.40M202.71M218.79M
Shares Outstanding ------143.11M145.08M147.77M153.78M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -34.86M-32.26M205.40M-149.68M--183.94M-156.32M-95.21M-45.99M
Investing Cash Flow 36.43M736.00K-481.70M-117.04M-2.90M129.65M77.79M37.95M
Financing Cash Flow 50.03M1.25M319.92M293.59M-132.26M2.25M241.00K30.40M
Capital Expenditure -2.42M-6.30M-11.20M-18.80M--16.35M-10.70M-3.66M-2.96M
Free Cash Flow -37.28M-38.56M194.20M-168.49M--200.29M-167.02M-98.88M-48.95M
Net Change in Cash ------48.77M-24.43M-17.18M22.37M

Ratios (Annual)

Figures in %.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----68.7%55.6%59.7%74.2%
Operating Margin % -115.7%-89.4%-92.1%-155.3%-135.4%-108.0%-118.4%-86.8%-20.6%
Net Margin % -111.4%-83.4%-80.6%-148.6%-134.3%-108.0%-132.3%-89.1%-21.5%
ROE % 19.1%18.0%-12.0%-19.7%--43.1%-73.0%-78.7%-27.2%
ROCE % --16.1%-9.4%-15.1%--26.8%-35.2%-35.2%-13.5%

Shareholding Pattern

Insiders
1.29%
Institutions
99.50%
Public Float
100.80%

Top Institutional Holders

#Holder% HeldSharesValue
1 Viking Global Investors, L.P. 18.79% 29.99M $794.53M
2 Blackrock Inc. 9.49% 15.14M $401.04M
3 Vanguard Capital Management LLC 4.01% 6.40M $169.63M
4 Wellington Management Group, LLP 3.70% 5.91M $156.59M
5 Vanguard Portfolio Management LLC 3.43% 5.48M $145.07M
6 Shaw D.E. & Co., Inc. 2.90% 4.63M $122.54M
7 Westfield Capital Management Co LP 2.67% 4.27M $113.05M
8 Geode Capital Management, LLC 2.28% 3.64M $96.47M
9 State Street Corporation 2.17% 3.46M $91.61M
10 Invesco Ltd. 1.94% 3.09M $81.96M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ADPT

Yahoo Finance hu, 08 Oct 2026

Adaptive Biotechnologies (ADPT) Stock Sees Modest Fair Value Lift On MRD Optimism

Adaptive Biotechnologies now sits on a higher modeled fair value, with the price target moving from US$26.36 to US$28.31 per share. This shift reflects how analysts are weighing strong enthusiasm around the clonoSEQ minimal residual disease…

Yahoo Finance Fri, 25 Sep 2026

Adaptive Biotechnologies (ADPT) Stock Could Be 26% Above Fair Value Despite Guideline Update

Adaptive Biotechnologies has seen its share price move sharply in recent years, and the question now is whether the cash flows the business can generate really back up that kind of ride. With the stock recently closing at US$29.57 and inves…

Yahoo Finance Fri, 25 Sep 2026

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

Definition requires five years off myeloma treatment with sustained MRD negativity, assessed with technology sensitive enough to identify one myeloma cell among one million cellsSEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechno…

Yahoo Finance hu, 24 Sep 2026

NCCN’s Myeloma MRD Update Spotlighting clonoSEQ Could Be A Game Changer For Adaptive Biotechnologies (ADPT)

Adaptive Biotechnologies recently highlighted updates to the National Comprehensive Cancer Network multiple myeloma guidelines, which now feature a dedicated page on minimal residual disease testing and specifically reference its FDA-cleare…

Yahoo Finance Wed, 23 Sep 2026

Adaptive Biotechnologies (ADPT): Can Blood Cancer Guidelines Boost Repeat Testing?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) highlighted updated National Comprehensive Cancer Network, or NCCN, multiple myeloma guidelines on September 17. According to the announcement, the recommendations specifically name clonoSE…

Yahoo Finance hu, 17 Sep 2026

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10-6 sensitivity now preferred SEATTLE, Sept. 17, 2026…

ADPT — Frequently Asked Questions

What is the current share price of Adaptive Biotechnologies Corporation (ADPT)?

As of 2026-10-22 16:30 PDT, Adaptive Biotechnologies Corporation (ADPT) trades at $24.41 on NasdaqGS. Its 52-week range is $12.30 to $29.84.

What is the market capitalisation of ADPT?

Adaptive Biotechnologies Corporation (ADPT) has a market capitalisation of $3.90B on NasdaqGS.

What is the P/E ratio of ADPT?

ADPT trades at a trailing price-to-earnings (P/E) ratio of -58.12. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 29.50.

What is the return on equity (ROE) of ADPT?

ADPT has a return on equity (ROE) of -38.76%. Its return on capital employed (ROCE) is -13.51%.

Is ADPT a good stock to buy?

This page provides a data-driven analysis of Adaptive Biotechnologies Corporation (ADPT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space